Clinical trials: Throat Carcinoma
Nasopharyngeal Carcinoma
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
The investigators have designed a multicenter, open-label, randomized controlled phase III clinical study of GAPP induction therapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy for high-risk…
- Trial name
- NCT07540390
- Testing
- Toripalimab, Anlotinib, Cisplatin
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Perioperative/Postoperative Complications
Transoral Robotic Surgery or Standard Surgery in Treating Patients With Benign or Malignant Tumors of the Larynx and Pharynx
RATIONALE: Transoral robotic surgery may make it easier to find and remove benign or malignant tumors of the larynx and pharynx and cause less damage to normal tissue.
- Conditions
- Head and Neck Cancer, Perioperative/Postoperative Complications, Precancerous Condition
- Trial name
- NCT00918762
- Testing
- assessment of therapy complications, diagnostic endoscopic surgery, quality-of-life assessment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Laryngeal Cancer, Hypopharynx Cancer
Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma
The aim of this study is to define whether combination of induction chemotherapy and PD-1 inhibitor (Toripalimab) improve the rate of larynx preservation, for patients with resectable laryngeal/hypopharyngeal carcinoma.
- Conditions
- Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
- Trial name
- INSIGHT (NCT04995120)
- Testing
- chemotherapy TP regimen combined with Toripalimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.
This is an open label, single-arm, multi-center, phase 2 Study of SHR-1210 in recurrent/metastatic nasopharyngeal carcinoma(R/M NPC) patients who have received previous at least two lines of chemotherapy.
- Trial name
- NCT03558191
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Cancer
Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma
This study evaluates whether some patients with nasopharyngeal carcinoma but with low risk of distant metastasis can be treated with only radiotherapy and concomitant chemotherapy but without additional adjuvant chemotherapy.
- Trial name
- NCT03175939
- Testing
- Radiotherapy, Cisplatin, 5-FU
- Volunteers
- 263 people
- Sponsor
- Sun Yat-sen University
Wilms Tumor, Fibrosarcoma
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.
- Conditions
- Wilms Tumor, Fibrosarcoma, Carcinoma, Round Cell, Nasopharyngeal Cancer
- Trial name
- NCT00141765
- Testing
- Myeloablative Chemotherapy, Stem Cell Rescue
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Nasopharyngeal Carcinoma
Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma
This trial is a prospective, parallel controlled, randomized, open, multi-center phase III clinical trial. The trial will enroll 364 patients with nasopharyngeal carcinoma who are staged T1-2N0-1M0 (except T1N0M0) (UICC 8th…
- Trial name
- NCT04766359
- Testing
- Albumin-Bound Paclitaxel
- Volunteers
- 364 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Head and Neck Squamous Cell Carcinom, Nasopharyngeal Carcinoma
The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC
A phase I/II clinical study of JS004 in subjects with head and neck cancer in China, to evaluate the safety, tolerability, PK, immunogenicity, antitumor activity and biomarkers of JS004, define the RP2D.
- Trial name
- NCT04929080
- Testing
- JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion, JS001 and JS004
- Where
- China
- Volunteers
- 149 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life
Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer. The last three decades of research in head and neck radiation oncology have largely focused on improvements in survival, which have mostly come at the cost of long…
- Trial name
- NCT06136962
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC
Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients.
- Trial name
- NCT05549466
- Testing
- Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel), Apatinib, Camrelizumab, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Advanced Head and Neck Squamous Cell Carcinoma
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining CDX-3379 and cetuximab.
- Trial name
- NCT03254927
- Testing
- CDX-3379 and cetuximab
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Celldex Therapeutics
Metastatic Nasopharyngeal Carcinoma
Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment
to evaluate the efficacy and safety of toripalimab and capecitabine maintenance therapy in patients with metastatic nasopharyngeal carcinoma (NPC) after first-line gemcitabine/cisplatin combined with toripalimab.
- Trial name
- NCT05484375
- Testing
- Capecitabine plus toripalimab
- Volunteers
- 40 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Oropharynx Cancer, Oropharynx Neoplasm
Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer
The aim of the study was to examine the detection rate and tumor size evaluation in patients with suspected oropharynx cancer using a new technique with transoral ultrasound of the oropharynx.
- Conditions
- Oropharynx Cancer, Oropharynx Neoplasm, Tonsil Cancer, Tonsil Neoplasm
- Trial name
- NCT05698667
- Testing
- Transoral ultrasound, Transcervical ultrasound
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Nasopharyngeal Carcinoma
Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients
In this study, a single-arm, open-labeled clinical trial will be performed to determine the safety and efficacy of EBV TCR-T cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma with positive EBV infection in…
- Trial name
- NCT03925896
- Testing
- LMP2 Antigen-specific TCR T cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sun Yat-sen University
The Aim of Our Study is to Prospectively Evaluate the Optic Neuropathy in Nasopharynx Cancer Patients
OPHTHALMOLOGIC EVALUATION OF RADIATION-RELATED OPTIC NEUROPATHY FOLLOWING IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY (IMRT) FOR NASOPHARYNGEAL CARCİNOMA
Primary treatment in nasopharynx cancers is radiotherapy (RT) or chemoradiotherapy (CRT) depending on the stage of the tumor. According to the guidelines, the dose of radiotherapy for primary tumors varies between 66-70 Gy.
- Trial name
- ORONIN (NCT04724590)
- Testing
- IMRT(IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY )
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma
- Trial name
- NCT00091182
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare concurrent chemoradiotherapy plus adjuvant chemotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced NPC, in order to evaluate the value of adjuvant…
- Trial name
- NCT00677118
- Testing
- Cisplatin,fluorouracil, Cisplatin
- Where
- China
- Volunteers
- 506 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma
This is the first phase II randomized clinical trial of concurrent chemoradiotherapy with or without EGFR blocker Nimotuzumab for high risk advanced nasopharyngeal carcinoma(NPC) , determining whether concurrent…
- Trial name
- NCT04223024
- Testing
- CCRT+Nimotuzumab, CCRT alone
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients
NPC Patients receiving IMRT treatment will receive a dedicated FDG PET/CT and high-sensitivity PET/CT protocol simultaneously in the follow-up of Locally Advanced Nasopharyngeal Carcinoma.
- Trial name
- NCT04394091
- Testing
- ultrasensitive PET CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.